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A number of biomonitoring surveys have been performed for chlorpyrifos (CPF) and its metabolite (3,5,6-
trichloro-2-pyridinol, TCPy); however, there is no available guidance on how to interpret these data in a
health risk assessment context. To address this gap, Biomonitoring Guidance Values (BGVs) are devel-
oped using a physiologically based pharmacokinetic and pharmacodynamic (PBPK/PD) model. The
PBPK/PD model is used to predict the impact of age and human variability on the relationship between
an early marker of cholinesterase (ChE) inhibition in the peripheral and central nervous systems [10% red
blood cell (RBC) ChE inhibition] and levels of systemic biomarkers. Since the PBPK/PD model character-
izes variation of sensitivity to CPF in humans, interspecies and intraspecies uncertainty factors are not
needed. Derived BGVs represent the concentration of blood CPF and urinary TCPy associated with 95%
of the population having less than or equal to 10% RBC ChE inhibition. Blood BGV values for CPF in adults
and infants are 6100 ng/L and 4200 ng/L, respectively. Urinary TCPy BGVs for adults and infants are
2100 lg/L and 520 lg/L, respectively. The reported biomonitoring data are more than 150-fold lower
than the BGVs suggesting that current US population exposures to CPF are well below levels associated
with any adverse health effect.
 2015 The Dow Chemical Company and Summit Toxicology, LLP. Published by Elsevier Inc. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Chlorpyrifos (CPF) (O,O-diethyl O-(3,5,6-trichloro-2-pyridyl)
phosphorothioate) is an insecticide used to control a broad-spec-
trum of insect pests. CPF is not persistent in the environment
and does not bioaccumulate. The compound is metabolized in both
insects and mammals (USEPA, 2011). CPF was ﬁrst registered in theUnited States (US) in 1965 and it is used in over 100 countries to
protect more than 50 different crop types against insect pests. Reg-
istered uses of CPF in the US include food crops such as fruit and
nut trees and many fruits, vegetables, and grains. Non-food crop
applications include forage, golf course turf, industrial sites, green-
house and nursery production, sod farms, and wood products
(USEPA, 2011). Because CPF was withdrawn from residential use
in the US in 2001, the primary route of chlorpyrifos exposure to
the general population is via dietary residues (USEPA, 2011).
Human exposure to CPF has been investigated in multiple bio-
monitoring studies of the general population and occupationally
exposed subpopulations. These studies generally employed mea-
surements of the parent CPF in blood or its major metabolite,
3,5,6-trichloro-2-pyridinol (TCPy), in urine (Alexander et al.,
2006; Barr et al., 2005; Centers for Disease Control and
Prevention (CDC), 2009; Farahat et al., 2011; Garabrant et al.,
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surements of blood CPF and urinary TCPy to levels associated with
potential health effects have been lacking.
This manuscript describes a novel methodology that uses a
physiologically based pharmacokinetic and pharmacodynamic
(PBPK/PD) model to derive Biomonitoring Guidance Values (BGVs)
for measurements of blood CPF and urinary TCPy. The BGVs repre-
sent the blood CPF and urinary TCPy levels predicted to occur in
sensitive individuals exposed to an oral acute dose that results in
10% red blood cell (RBC) cholinesterase (ChE) inhibition (the early
marker of ChE inhibition in the peripheral and central nervous sys-
tems). The BGVs are then compared to actual CPF biomonitoring
data from a number of studies and margins of safety (MOSs) are
generated. The MOSs can then be used to inform whether popula-
tions are at potential risk.2. Background
2.1. CPF metabolism
Oral doses of CPF are well absorbed and undergoe extensive
ﬁrst pass metabolism (Bakke et al., 1976; Smith et al., 1967;
Nolan et al., 1984, 1987; Timchalk et al., 2006; Grifﬁn et al.,
1999). When CPF enters the body it is initially metabolized by
cytochrome (CYP) P450s, mainly in the liver, to primarily TCPy or
diethylphosphate (DEP) metabolites or to the trace-level, short-
lived CPF-oxon metabolite. Minor CYP metabolism also occurs in
the intestine, lung, skin, and brain (Poet et al., 2014b), and CPF is
known to irreversibly inhibit CYP P450s (Eaton et al., 2008). The
low levels of CPF-oxon that are formed are rapidly metabolized
to TCPy in both the liver and circulating blood (Fig. 1) by paraoxon-
ase (PON1) and other esterases (Eaton et al., 2008).
In rats, CPF is primarily excreted in the urine as conjugates of
TCPy (Bakke et al., 1976; Smith et al., 1967). Nolan et al. (1987) also
studied CPF metabolism in the rat and found that it undergoes
extensive ﬁrst-pass metabolism to TCPy, with no parent compound
excreted in urine. These authors reported the major urinary metab-
olite to be TCPy-glucuronide, with lesser amounts of TCPy-sulfate
and free TCPy (Nolan et al., 1987). Sunaga et al. (1989) reportedN O
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Fig. 1. Metabolic scheme of csimilar ﬁndings, following intraperitoneal administration of CPF
to rats, showing urinary TCPy accounted for more than 85% of
the administered dose of CPF, with lower percentages of the dieth-
ylphosphate metabolites recovered. A subsequent study was con-
ducted in rats to evaluate the time-course of blood metabolites
following oral administration of 0.5–100 mg CPF/kg body weight
(Timchalk et al., 2006). The authors determined 99% of blood
metabolites were in the form of TCPy with only 1% as parent com-
pound. Trace levels of CPF-oxon levels were found but were gener-
ally 100-fold lower than CPF levels. These trace levels of the CPF-
oxon metabolite are consistent with the report of high ﬁrst-pass
metabolism of CPF by the liver (Sultatos, 1994).
The metabolism and pharmacokinetics of CPF have been evalu-
ated in several human volunteer studies. Nolan et al. (1984) found
at least 70% of a single oral dose of CPF (0.5 mg/kg) was absorbed
and excreted in the urine, primarily as acid-labile conjugates of
TCPy (Nolan et al., 1984). Trace levels of CPF were found in this
study, with no measurements conducted for CPF-oxon (Nolan
et al., 1984). Grifﬁn et al. (1999) measured urinary DEP metabolites
of CPF following oral or dermal doses, showing 93% of adminis-
tered dose is excreted in urine as these DEP metabolites. In a later
multi-dose level pharmacokinetic study, Kisicki et al. (1999) found
that following a single oral dose of either 0.5, 1.0 or 2.0 mg CPF/kg
body weight, TCPy was the major metabolite in blood, with CPF
levels <1% of TCPy concentrations. No CPF-oxon was detected in
blood samples from this study, with the 1 ng/mL limit of quantita-
tion value 3- to 18-fold lower than the highest CPF concentrations
observed. These CPF-oxon results are consistent with the rat phar-
macokinetic results and indicate that CPF undergoes extensive
ﬁrst-pass metabolism in humans as well as animals.2.2. CPF mode of action
The mode of action for CPF has been well described (Eaton et al.,
2008). CPF is lipophilic with a logKow value of 4.96 (Sangster, 1994);
whereas, the CPF-oxon and hydrolysis metabolites, TCPy and dieth-
ylphosphates, are substantially more polar. The parent compound;
containing the P@S bond is more chemically stable than the reac-
tive CPF-oxon, due to the P@S bond being less electronegative thanOH
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stabilizes CPF from loss of TCPy (Ballantyne and Marrs, 1992;
Chambers and Levi, 1992). As a result, toxicological effects are
ascribed to the more reactive CPF-oxon rather than CPF (Sultatos,
1994). Toxicological effects arising from formation of the CPF-oxon
metabolite are primarily via inhibition of ChE activity, through
covalent binding of CPF-oxon to the serine active site of this class
of enzymes (Thompson et al., 2010). The inhibition of the enzyme
results in accumulation of acetylcholine at neuronal junctions and
causes hyperactivity of nervous tissues leading to a range of apical
effects in multiple tissues (Eaton et al., 2008).
The USEPA has concluded that inhibition of ChE represents the
most sensitive effect of CPF in animals and humans (USEPA, 2011).
While USEPA Policy (USEPA, 2000) recognizes the importance of
ChE inhibition in the peripheral and central nervous system in haz-
ard evaluation, in the absence of these data, USEPA uses RBC ChE
inhibition as a surrogate measure for ChE inhibition in the periph-
eral and central nervous systems. RBC ChE inhibition is not an
adverse effect per se, but is readily measured and occurs at lower
doses than inhibition in the peripheral and central nervous sys-
tems. It should be noted that data exists on ChE inhibition in both
central and peripheral nervous systems for CPF in dogs (Marable
et al., 2007). Consistent with the risk assessment for other organo-
phosphate compounds, the USEPA has used a response level of 10%
RBC ChE inhibition as the endpoint to predict the point of depar-
ture for the acute and chronic oral exposure benchmarks (i.e., acute
and chronic Population Adjusted Doses) for CPF (USEPA, 2011).
2.3. Biomarkers of exposure and effect
Controlled animal toxicokinetic experiments and human volun-
teer studies have identiﬁed a number of biomarkers of exposure
and effect (i.e., ChE inhibition), and these have been used to vali-
date the PBPK/PD model for CPF. As shown in Table 1, these bio-
markers include CPF, CPF-oxon and TCPy metabolites in blood
and urine, as well as ChE inhibition in plasma, red blood cells
(RBCs) and other tissues.
2.4. PBPK/PD model
CPF is a data-rich chemical with multiple in vitro and in vivo ani-
mal and human data sets that have deﬁned CPF metabolism, the
mechanism of action, and multiple markers for exposure and
effect. These data have permitted the development of a robust
and well-validated PBPK/PD model that quantitatively predicts
the concentration of biomarkers (i.e., CPF in blood and TCPy in
urine) and RBC ChE inhibition (Hinderliter et al., 2011; Juberg
et al., 2011; Price et al., 2011; Poet et al., 2014a).
Timchalk et al. (2002) published the ﬁrst CPF PBPK/PD model
and the model has been reﬁned in subsequent publications. TheTable 1
Toxicokinetic and cholinesterase (ChE) inhibition biomarkers of CPF exposure or effect us
Exposure route ChE inhibition
Plasma RBC Diaphragm /lung Brain
Oral
Rat    
Human  
Dermal
Rat   
Human  
Inhalation
Rat    
Humanenhancements of the model include reﬁning estimates of ChE inhi-
bition rates and CYP P450 metabolism rates with measured in vivo
and in vitro human and animal data. The model also includes
metabolism in the intestines and other non-hepatic tissues (Price
et al., 2011; Smith et al., 2014; Poet et al., 2014a,b).
The model is coded in acslXtreme (Aegis Technology, Hunts-
ville, AL). The model has been primarily parameterized and vali-
dated using human data from in vitro and in vivo studies, and by
a lesser extent by ﬁtting the model to human exposure data. Data
on human physiology is based on the growth models described by
Luecke et al. (2007) and Young et al. (2009). CPF speciﬁc metabo-
lism was measured in vitro and describes the detoxiﬁcation to TCPy
and bioactivation to CPF-oxon in the liver. The model describes the
pharmacokinetics of CPF and pharmacokinetics and pharmacody-
namics of CPF-oxon, the active metabolite of CPF, and a more sim-
pliﬁed single compartment with a volume of distribution and ﬁrst-
order urinary elimination for TCPy. The model is able to predict CPF
and CPF-oxon concentrations over time in the fat, slowly perfused
tissue, rapidly perfused tissue, diaphragm, brain, and liver
compartments.
The submodel that describes the active oxon includes biomolec-
ular rate constants to describe inhibition of cholinesterases (acetyl
ChE and butyryl ChE) and carboxylesterase inhibition in multiple
tissues. The modeling of these tissues also includes descriptions
of reactivation and aging of these enzymes (Smith et al., 2014).
The resultant model has been shown to predict the concentration
of CPF in blood and TCPy in urine as well as inhibition of plasma
butyryl ChE and RBC ChE in exposed individuals (Juberg et al.,
2011).
The version of the model used to set the BGVs assesses interin-
dividual variation in RBC ChE inhibition in populations of humans
of different ages that occurs as a result of interindividual differ-
ences in physiology and metabolic capacity. The model character-
izes interindividual variation in response using Monte Carlo
analysis. The interindividual variation in model predictions include
blood CPF and urinary TCPy concentrations as well as inhibition of
plasma butyryl ChE and RBC ChE (Juberg et al., 2011; Price et al.,
2011; Poet et al., 2014a).
Monte Carlo models require data on interindividual variation in
the inputs to the PBPK/PD model. There are approximately 120
inputs for the PBPK/PD model used to set the BVGs (Smith et al.,
2014). Many of the inputs do not vary across individuals, and other
inputs vary but the model predictions are not sensitive to this var-
iation. As a result, the Monte Carlo model does not require distri-
butions for these inputs. The impacts of interindividual variation
in model inputs on the model predictions were determined by per-
forming a sensitivity analysis. In this analysis a small change, 1%,
was made in the value of each parameter and the impact of the
change on peak RBC ChE inhibition was determined. Only sixteen
of the inputs were identiﬁed as having some impact on peak RBCed to validate the PBPK/PD model (adapted from Poet et al., 2014b).
Toxicokinetic
Blood CPF Blood CPF-oxon Blood TCPy Urine TCPy
   
   
  
   
Table 2
Parameters showing a sensitivity coefﬁcient greater than 0.1 in the local sensitivity analysis after a 1 mg/kg/day dose (adapted from Poet et al., 2014a).
Parameter Sensitivity coefﬁcienta
infant
Mean value for Monte Carlo
distribution
Coefﬁcient of
variation
Variability references
Total blood volume 1.18 Age-dependentb 0.03c Price et al. (2003)
Plasma paraoxonase (PON1) 1.18 Age-dependentb 0.53d Smith et al. (2011)
Hepatic blood ﬂow (L/h  kg tissue) 1.18 50 0.27 Materne et al. (2000)
Red blood cell (RBC) cholinesterase (ChE) inhibition rate
(l/lmol  h)
1.15 100 0.17 Dimitriadis and Syrmos
(2011)
Hepatic PON1 (lmol/h  kg tissue) 1.02 1.5e5 0.57d Smith et al. (2011)
Hematocrit (%) 0.45 0.45 0.068 Price et al. (2003)
RBC ChE degradation rate (l/h) 0.63 0.01 0.14 Chapman and McDonald
(1968)
Hepatic CYP P450 bioactivation to oxon
(lmol/h  kg tissue)
0.62 690 0.59 Smith et al. (2011)
Hepatic CYP P450 Detoxiﬁcation to TCPy
(lmol/h  kg tissue)
0.62 1.5e3 0.53 Smith et al. (2011)
RBC ChE reactivation rate (l/h) 0.49 0.014 0.36 Mason et al. (2000)
Intestinal CYP P450 bioactivation to oxon
(lmol/h  kg tissue)
0.48 82 0.52e Obach et al. (2001)
Intestinal CYP P450 detoxiﬁcation to TCPy
(lmol/h  kg tissue)
0.43 53 0.52e Obach et al. (2001)
Transfer rate to intestine (h1) 0.41 0.31 0.26c Singh et al. (2006)
Volume of the liver 0.26 Age-dependentb 0.03c Price et al. (2003)
Hepatic carboxyl basal activity rate (l/h/kg tissue) 0.25 1.27e6 0.36 Pope et al. (2005)
Hepatic carboxyl reactivation rate (l/h) 0.10 0.014 0.36 Mason et al. (2000)
Parameters are listed in descending order of sensitivity. The sensitivity of most parameters was greater in infants than adults. For clarity only infants are shown. These 16
parameters accounted for >95% of all model sensitivity.
a Local sensitivity analysis following a repeated 3 lg/kg/day dose in both infants and adults resulted in no parameters more sensitive than 0.001.
b Age-speciﬁc parameters are calculated using a polynomial equation, see Smith et al. (2014).
c The sensitivity of blood and liver volume were assessed based on the ﬁrst term in a age-dependent calculation formula that predicts total volume normalized to body
weight for an individual of a speciﬁc age. These parameters are likely more sensitive than the ﬁnal parameter since small changes in the ﬁrst term will be carried through the
equation. Despite this, to be conservative, the total blood and liver volume were varied. The variability shown here is for the parameter prior to multiplying by body weight.
d Plasma and hepatic PON1 were linked in the ﬁnal analyses using the same coefﬁcient of variation.
e Based on intestinal metabolism of testosterone.
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1% change in the input value results in a corresponding change
in RBC ChE inhibition of at least 0.1%). These inputs account for
greater than 95% of the summed sensitivities of all inputs (Table 2).3. Methodology
3.1. Description of BGVs
The BGV developed using the PBPK/PD builds on the concept of
Biomonitoring Equivalents (BEs) (Hays et al., 2007). The BE meth-
odology uses available pharmacokinetic data and forward dosime-
try to calculate levels of biomarkers associated with exposures that
are consistent with general population exposure guidance values
(e.g., Reference Doses, Minimal Risk Levels, or Tolerable Daily
Intakes) (Hays et al., 2008). Over 100 BEs for a wide range of chem-
icals have been derived to date (Aylward et al., 2013). BEs are risk-
based screening tools designed to help interpret human biomoni-
toring data in a public health risk context. The BGVs are intended
to be used in the same ways as BE values; however unlike BEs,
BVGs are not based on existing exposure guidance values. The
approach described here for the ﬁrst time instead uses a PBPK/PD
model of interindividual differences in human metabolism and
physiology to assess the relationship between biomarker concen-
trations and RBC ChE inhibition (Juberg et al., 2011; Poet et al.,
2014a).
The BGVs derived here are conceptually similar to biological
exposure limits established by the German Human Biomonitoring
Commission using epidemiology studies. Known as human bio-
monitoring (HBM-I) values, they are described by Angerer et al.
(2011) as ‘‘the concentration in the body matrix of a substance
below which, according to the Commission’s current assessment,no adverse health effect should be expected. Thus, no action will
be needed from a toxicological perspective if concentrations are
below the HBM-I value’’. Angerer and colleagues further state that
when HBM-I are based on epidemiological studies, the HBM-I lev-
els reﬂect the highest biomarker concentration where adverse
effects are not expected to occur.3.2. Derivation of BGV values for CPF in blood and TCPy in urine
The methodology used in setting the BGV values for CPF in
blood and TCPy in urine is as follows. The PBPK/PD model is used
to predict the concentration of CPF in blood and TCPy in urine that
will occur when an individual receives a single oral dose that
causes 10% inhibition of RBC ChE and how these values vary across
individuals as a result of interindividual differences in physiology
and metabolism. The model can also address age-related differ-
ences in these relationships.
The BGV levels for CPF in blood and TCPy in urine are based on
the modeling of single daily dietary exposures rather than a contin-
uous exposure to a speciﬁc dose. Models of longitudinal dietary
exposures have shown that CPF exposures of all individuals vary
greatly from one day to the next, and as a result, elevated dietary
exposures occur as independent and isolated events in an individ-
ual’s exposure history. This variation occurs because an individ-
ual’s diet typically varies from one day to the next and even
when it does not, the residue levels vary from one food item to
the next (Juberg et al., 2011; Price et al., 2011).
Adults 30 years of age and infants six months of age were
modeled to provide age-speciﬁc BGV values that could be used
to evaluate published CPF biomonitoring data for these ages.
The PBPK/PD model produces an estimate of the amount of TCPy
excreted in the urine over a 24-h period. These data were used
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Fig. 2. Average daily red blood cell (RBC) cholinesterase (ChE) inhibition from a
single daily dose of chlorpyrifos from 0.005 mg/kg to 5 mg/kg in 100,000 simulated
infants. Each data point is the average RBC ChE inhibition for the 24 h following a
single oral dose. The horizontal line marks 10% RBC ChE inhibition.
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excreted per gram of creatinine using published values for age-
and gender-speciﬁc urine production and creatinine elimination.
The average urinary ﬂow used for infant and adults are 79.3 mL/
kg/day and 18.0 mL/kg/day, respectively (Heffernan et al., 2013).
Adult creatinine clearance was assumed to be 0.201 mmol/kg/
day in males and 0.182 mmol/kg/day in females based on data
in adolescents (Remer et al., 2002). Data on creatinine clearance
was not identiﬁed for infants; therefore, the Remer et al. (2002)
data reported for 3 year-old-children was applied for infants
(0.134 mmol/kg/day in male children and 0.127 mmol/kg/day in
female children).
Following an oral dose, the spot urine concentration of TCPy,
blood concentration of CPF, and the degree of RBC ChE inhibition
varies over 24-h (Hinderliter et al., 2011). The use of the central
tendency or mean concentration for spot samples of chemicals
with a short half-life has been recommended (LaKind et al.,
2008). Therefore, the BGV for urine and blood are deﬁned as the
average concentrations of TCPy in urine and CPF in blood that will
occur in an individual over the 24-h period following a dose that
causes an average of 10% inhibition of RBC ChE for the 24-h period.
For a given single oral dose, the PBPK/PD was used to estimate
the 24-h average of: (1) the level of RBC ChE inhibition, (2) the con-
centration of CPF in blood, and (3) the concentration of TCPy in
urine. This was repeated for 100,000 adults and 100,000 infants
(varying model parameters as noted in Table 2) exposed to a log
uniform range of randomly generated doses ranging from
0.005 mg/kg to 5 mg/kg. This range of doses was predetermined
to cover the range of adult and infant sensitivities to CPF (Poet
et al., 2014a).
For the concentration of TCPy in urine, the results were sorted
from the lowest to highest TCPy concentration and a 1000 person
running average was determined. For each set of 1000 individuals,
the fractions of individuals with less than or equal to 10% RBC ChE
inhibition were determined. The sets of individuals where 5%, 50%,
and 95% of the individuals had RBC ChE inhibition of 10% or less
were identiﬁed and the mean value of the concentration of TCPy
in urine for each group was determined. The value of the average
concentration of TCPy in urine for the group of 1000 individuals
where 95% of the group have RBC ChE inhibition of 10% or less
was used as the basis for the BGVs for TCPy in urine. The same pro-
cedure was repeated with blood CPF as the dose metric to produce
the BGV for CPF in blood.
Traditional BE values derived using the point of departure
from a regulatory standard are corrected using uncertainty factors
determined in the underling risk assessment to account for inter-
individual and interspecies PK/PD differences (Hays et al., 2007).
The BGV values generated here using the PBPK/PD model; how-
ever, do not require any additional adjustment factors. The
PBPK/PD model predicts the time-varying extent of response
(RBC ChE inhibition) directly in humans; therefore, there is no
need for an interspecies adjustment factor. The BGV levels are
based on a model of the most sensitive age and on the lower per-
centile of a concentration range that reﬂect human variation in
response; therefore, there is no need for an intraspecies adjust-
ment factor.
The urinary and blood BGV values generated in the above pro-
cess are based on simulations of the relationships between single
oral doses and the concentrations of CPF in blood and TCPy in
urine. As a result, the values of the BGVs are speciﬁc to exposures
to dietary residues and other oral sources that have a high day-to-
day variability. However, the BGVs may be relevant for individuals’
whose exposures could occur over longer periods of time and by
other routes if those exposures resulted in the same relationships
between RBC ChE inhibition and concentrations of CPF in blood
and TCPy in urine.4. Results
4.1. PBPK/PD modeling and derivation of BGVs
Fig. 2 presents the results for the PBPK/PD model for RBC ChE
inhibition as a function of a single oral daily dose in a simulated
population of 100,000 infants for the dose range of 0.005 mg/kg–
5 mg/kg of CPF. The data for adults (not shown) are similar. In
the dose response for an individual, the responses to any dose fall
on a single curve. But in a population of individuals with variation
of metabolism and physiology, the model predictions appear as a
cloud. The horizontal line marks 10% RBC ChE inhibition. The range
of 10% RBC ChE inhibition for the simulated population falls within
a range of 0.08 mg/kg–3 mg/kg. This is consistent with earlier esti-
mates (Juberg et al., 2011).
Fig. 3 presents the 95th, 50th, and 5th percentiles of the distribu-
tions of blood CPF and urinary TCPy concentrations for the 100,000
simulated infants, and Tables 3 and 4 present the blood CPF and uri-
nary TCPy concentrations corresponding to these percentiles for
adults and infants. As Table 3 indicates, there are approximately a
10-fold and 9-fold difference between the 5th (i.e., the biomarker
concentration associated with 5% of the population having a RBC
ChE inhibition of 10% or less) and 95th percentiles (i.e., the bio-
marker concentration associated with 95% of the population having
a RBC ChE inhibition of 10% or less) for blood CPF and urinary TCPy
and about a 3-fold difference between the medians (i.e., the bio-
marker concentration associated with 50% of the population having
a RBC ChE inhibition of 10% or less) and 95th percentiles. Table 3
presents the predicted levels for the concentration of TCPy in urine
(lg/L), the mass excretion rate of TCPy per hour adjusted for body
weight (lg TCPy excreted per kg body weight per hour – lg/kg/
h), and the lg of TCPy per gram of creatinine.
The age-related differences are generally smaller than the dif-
ferences between individuals of a given age and vary with the bio-
marker. BGV values for CPF in blood are a third lower for infants
compared to adults (Tables 3 and 4). The age-related differences
for the three BGVs for TCPy in urine also differ. These differences
are inﬂuenced by the units used to normalize TCPy in urine. When
reported on a concentration basis, the BGV is lower in infants as
compared to adults, reﬂecting the greater body weight normalized
urine production rate in infants. When reported on a creatinine
basis, the BGV is higher in infants, reﬂecting the greater excretion
rates of creatinine in adults (expressed on a bodyweight basis).
When expressed as a body weight normalized total mass excreted
basis, the values are nearly identical (Tables 3 and 4).
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Fig. 3. Average daily red blood cell (RBC) cholinesterase (ChE) inhibition from a
single daily dose of chlorpyrifos (CPF) ranging from 0.005 mg/kg to 5 mg/kg in
100,000 simulated infants compared to (A) 24-h average concentration of TCPy in
urine or (B) 24-h average blood CPF concentration. Gray lines delineate the 95th,
50th, and 5th percentiles of RBC inhibition across the population as a function of
biomarker concentration. The horizontal line marks 10% RBC ChE inhibition.
Table 3
Concentrations of chlorpyrifos in blood and TCPy in urine associated with the fraction
of the population of simulated adults with red blood cell (RBC) cholinesterase (ChE)
inhibition of less than or equal to 10%.
Percent of population
with 10% RBC ChE
inhibition
Blood
CPF
(ng/L)
Urinary
TCPy
(lg/L)
Urinary
TCPy (lg/
kg  h)
Urinary TCPy
(lg/g
creatinine)
95 6100 2100 2.0 1700
50 19,000 5700 5.6 4600
5 64,000 19,000 18 15,000
Table 4
Concentrations of chlorpyrifos in blood and TCPy in urine associated with fraction of
the population of simulated infants with red blood cell (RBC) cholinesterase (ChE)
inhibition of less than or equal to 10%.
Percent of population
with 10% RBC ChE
inhibition
Blood
CPF
(ng/L)
Urinary
TCPy
(lg/L)
Urinary
TCPy (lg/
kg  h)
Urinary TCPy
(lg/g
creatinine)
95 4200 520 2.2 2900
50 12,000 1300 5.3 7100
5 33,000 3800 16 21,000
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biomonitoring data
The proposed BGV values are protective of public health and
may be compared directly to human biomonitoring data to deter-mine aMOS. TheMOS is deﬁned here as the BGV divided by the bio-
monitoring data (BGV/biomonitoring data). The target MOS used
here is P1, reﬂecting the fact that the associated uncertainty fac-
tors (i.e., inter- and intra- species variability) have been accounted
for in the derivation of the BGV. For clarity, this term is different
than the term ‘‘Margin of Exposure’’, which is deﬁned in this con-
text as the ratio of the point of departure (such as a no observed
adverse effect level) and the estimated exposure dose or concentra-
tion. Since CPF and TCPy have short half-lives in the body and thus
would be expected to yield high intraindividual variability (Meeker
et al., 2005), the central tendency of biomonitoring levels from pop-
ulation surveys are most indicative of longer term average expo-
sures (Aylward et al., 2012; LaKind et al., 2008).
CPF can also be converted to TCPy in the environment. It is esti-
mated that approximately 80% of urinary TCPy is the result of
direct exposure to preformed environmental TCPy and not expo-
sure to CPF (MacIntosh et al., 2001; Wilson et al., 2003). Two other
pesticides chlorpyrifos-methyl and triclorpyr also are converted to
TCPy in the environment (Eaton et al., 2008). Therefore, caution
must be used when attempting to predict CPF exposure from mea-
sured levels of TCPy for populations where the predominant source
of exposure is dietary residues. To account for the other environ-
mental sources of TCPy, MOSs are also presented assuming that
20% of the observed TCPy in urine results from exposure to CPF
(Table 5).
Urinary TCPy has been detected in the general US population in
the CDC National Health and Nutrition Examination Survey
(NHANES) biomonitoring program (CDC, 2009) (Table 5). With
no legal residential uses since 2001, diet is the presumed route
of exposure and a substantial proportion of the measured TCPy
is due to ingestion of preformed environmental TCPy (Barr et al.,
2005). As shown in Table 5, urinary TCPy is ubiquitously detected
in children and adults. Using the relevant BGV and assuming that
all the TCPy was from the parent CPF, the MOSs for US children,
teens, and adults are 677, 583, and 1105, respectively. Using the
BGVs derived for infants, the MOSs for children are 168 and 839,
assuming 100% and 20% contribution of CPF, respectively.
Collected several years later, urinary TCPy results from a biomon-
itoring study of California families were slightly lower than the
CDC US general population data (Trunnelle et al., 2014). Urinary
TCPy levels for the children were just above the LOD (limit of
detection) with a resulting MOS of 1235 (100% from CPF) and
6176 (20% from CPF). Even using the most conservative assump-
tions (i.e., 100% TCPy was derived from CPF and using the infant
BGV value for children), the MOS of 306 indicates no RBC ChE inhi-
bition would be expected in this population. Other studies of preg-
nant women in which MOSs have been calculated indicate similar
results (Castorina et al., 2010; Whyatt et al., 2009; Yan et al.,
2009).
Recent studies have collected blood in pregnant women and
infant cord blood to measure parent CPF (Huen et al., 2012;
Whyatt et al., 2005; Yan et al., 2009). However, for blood CPF
(Table 6), CDC or similar national programs have not published
data representative of the general population. Notably, the geo-
metric mean blood CPF level in the New York City cohort declined
with the withdrawal of residential uses and by 2003 was not
detected in the New Jersey cohort (Eaton et al., 2008; Whyatt
et al., 2005; Yan et al., 2009). The MOSs are all well above 1 (when
the geometric mean was <LOD, the LOD was used to determine the
MOS). The California study reported by Huen et al. (2012) used a
different analytical technique and the LOD of 21 ng/L was higher
than the geometric mean values/LOD for the other cohorts. As a
result using the LOD as the exposure estimate, the estimated
MOS for this study is lower than the other studies, and may not
actually reﬂect a higher risk.
Table 5
Summary of the margin of safety (MOS) of TCPy in urine for selected US biomonitoring studies under assumptions of 100% of TCPy in urine is from direct exposure to chlorpyrifos
(CPF) or that only 20% of TCPy in urine is a result of direct exposure to CPF.
References Population Group Time period N LODa
(lg/L)
TCPy in urine MOS
50th percentile
(lg/L)
Assuming
100% CPF
Assuming 20%
CPF
Castorina et al. (2010) California pregnant
women
Prenatal, 13th week 1999–2001 538 0.3 2.1 1000c 5000c
CDC (2009) US population Ages 6–11 2001–2002 573 0.4 3.1 168b/677c 839b/3387c
Ages12–19 2001–2002 823 0.4 3.6 583c 2917c
Ages 20–59 2001–2002 1113 0.4 1.9 1105c 5526c
Whyatt et al. (2009) New York City pregnant
women
Prenatal, 34th week 2001–2004 95 0.3 0.5 4200c 21,000c
Maternal, day after
delivery
2001–2004 73 0.3 <LOD >7000c >35,000c
Yan et al. (2009) New Jersey pregnant
women
Maternal, day of
delivery
2003–2004 34 0.4 <LOD >5250c >26,250c
Trunnelle et al. (2014) California children Ages 2–8 2007–2009 83 0.6–1.2 1.7 306b/1235c 1529b/6176c
California parents Ages 18–57 2007–2009 90 0.6–1.2 1.2 1750c 8750c
a LOD (limit of detection) value used to calculate the MOS when the 50th% <LOD.
b The BGV derived for infants of 520 lg/L was used to determine the MOS.
c The BGV derived for adults of 2100 lg/L was used to determine the MOS.
Table 6
Summary of the margin of safety (MOS) for selected US biomonitoring studies of chlorpyrifos (CPF) in blood.
References Population Group Time period N LODa ng/L CPF in blood MOS
GMb ng/L
Huen et al. (2012) California mother/infant pairs Maternal, at delivery 1999–2001 234 21 <LOD >290d
Cord blood 1999–2001 256 21 <LOD >200c
Whyatt et al. (2005) and Eaton et al. (2008) New York City mother/infant pairs Maternal, at delivery 1999–2002 326 0.5 1.7 3588d
Cord blood 1999 109 0.5 3.7 1135c
Cord blood 2000 104 0.5 2.0 2100c
Cord blood 2001 67 0.5 <LOD >8400c
Cord blood 2002 9 0.5 1.1 3818c
Yan et al. (2009) New Jersey mother/infant pairs Maternal, at delivery 2003–2004 138 1 <LOD >6100d
Cord blood 2003–2004 148 1 <LOD >4200c
Yan et al. (2009) publication has an unit error. The CPF blood should be ng/L (Personal communication D. Barr).
a LOD (limit of detection) value used to calculate the MOS when the geometric mean <LOD.
b GM = geometric mean.
c The BGV derived for infants of 4200 ng/L was used to determine the MOS.
d The BGV derived for adults of 6100 ng/L was used to determine the MOS.
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5.1. BGVs and their implications for CPF biomonitoring
The use of human biomonitoring data where concentrations of
chemicals and/or their metabolites are measured in blood or urine
from a population or speciﬁc sub-populations is increasingly being
used as a preferred approach to assessing human exposure (Sexton
et al., 2004). Biomonitoring data reﬂect integrated exposure from
all routes and pathways (Hays et al., 2008). The concept of the
BE was designed to put these data into a human health risk context
(Hays et al., 2007). The BGVs presented here provide a robust
method that allows interpretation of biomarkers for CPF exposure
to the endpoint of interest, RBC ChE inhibition.
We propose to set the BGVs using the blood CPF and urinary
TCPy values that are associated with 95% of the population having
a RBC ChE inhibition rate less than or equal to 10%. Observed bio-
monitoring levels below the BGVs are unlikely to be associated
with RBC ChE inhibition, and since RBC ChE inhibition is a conser-
vative marker of ChE inhibition in the central and peripheral ner-
vous systems, the BGVs are expected to be protective against
actual adverse effects for adults and infants.The BGVs were developed using the assumption that diet was
the primary source of exposure and that high daily doses would
occur as isolated events (Juberg et al., 2011; Price et al., 2011).
Occupational exposures that can occur by multiple routes and
may be repeated over multiple days were not part of the modeling
exercise. However, the relationship between TCPy in urine and the
extent of RBC ChE inhibition observed in Egyptian workers (who
applied CPF to crops) are remarkably close to the same relationship
predicted here using the PBPK/PD model (Farahat et al., 2011).
Using TCPy concentrations from urine collected over 9–17 days
and data on RBC ChE levels, Farahat et al. (2011) calculated ‘‘inﬂec-
tion points’’ where RBC ChE inhibition was detected for various
groups of workers. The estimated inﬂection points in three groups
of workers ranged from urinary TCPy levels of 2000 lg/g creatinine
to 3200 lg/g creatinine. Using the PBPK/PD model, the TCPy levels
in urine that are predicted to cause a small amount of RBC ChE inhi-
bition (10%) in 50–95% of adults was estimated to be 4600 lg/g cre-
atinine to 1700 lg/g creatinine (Table 3). The close agreement of
the model ﬁndings with the Farahat et al. (2011) study suggests
that the relationship of TCPy excretion to RBC ChE inhibition is
likely to be independent of the route and duration of exposure. This
is an area where additional research could be performed.
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PBPK/PD modeling provides a useful tool for investigating the
relationship between observable biomonitoring measurements
and potential adverse effects. In the case of CPF, the model is able
to generate BGVs that can be used to evaluate biomarkers for CPF
in blood and TCPy in urine. The PBPK/PD model was constructed
and validated using human data. In addition, the results of the
model compared favorably to an Egyptian worker study where
ChE inhibition was observed. A comparison of the BGV levels to
available biomonitoring data suggests MOSs of greater than 150
for current US general population exposures. Such values indicate
that current exposure levels are well below a level that would pose
a potential risk to either adults or infants. If it is assumed 20% of
urinary TCPy is derived from CPF exposure, and the Huen et al.,
2012 study is disregarded because of the high blood CPF LOD, then
all MOSs are greater than 800.
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